| 產(chǎn)品編號(hào) | bsk11091 |
| 英文名稱 | Human OPG ELISA Kit |
| 中文名稱 | 人護(hù)骨素酶聯(lián)免疫試劑盒 |
| 別 名 | MGC29565; OCIF; OPG; Osteoclastogenesis Inhibitory Factor; TNFRSF 11B; TNFRSF11B; TR 1; TR1; Tumor Necrosis Factor Receptor Superfamily Member 11b; TR11B_HUMAN. |
| 克 隆 號(hào) | |
| 種 屬 | Human |
| 線性范圍 | 62.50 - 4,000 pg/mL |
| 應(yīng)用范圍 | S/P/CC |
| 檢測(cè)限 | 15 pg/mL |
| 適用樣品基質(zhì) | cell culture supernates, serum, and plasma. |
| 保存條件 | Store at 4°C for 6 months, at -20°C for 12 months. Avoid multiple freeze-thaw cycles (Shipped with wet ice.). |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 產(chǎn)品介紹 |
Osteoprotegerin (OPG, or osteoclastogenesis inhibitory factor) is a secretory glycoprotein belonging to TNF receptor superfamily. Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. OPG acts as a soluble factor in the regulation of bone mass and may be beneficial in the treatment of osteoporosis with increased osteoclast activity. OPG consists of 401 amino acids with a molecular weight of 44 kDa as a monomer and 90 kDa as a disulphide-linked dimer.
|
